ADT exposure after prostate cancer treatment is associated with the onset of dementia.
The nonrandomized, multicenter, multicohort, open-label, phase 1b/2 KEYNOTE-365 trial evaluated the safety, tolerability, and efficacy of pembrolizumab combination therapy in men with mCRPC.
Treatment discontinuation from adverse events in real-world use is 32% higher for apalutamide and 49% higher for enzalutamide than reported in clinical trials of patients with non-metastatic castration-resistant prostate cancer.
CRFS after relugolix was not significantly different compared with leuprolide in men with advanced prostate cancer and metastatic disease.
RT for prostate cancer is associated with distinct treatment-related complications such as cystitis and urinary stricture.